|
REGOMUNE: A phase II study of regorafenib plus avelumab in solid tumors—Results of the non-MSI-H metastatic colorectal cancer (mCRC) cohort. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bristol-Myers Squibb; Lilly; Novartis; Sanofi; SynCoreBio |
Travel, Accommodations, Expenses - Amgen; Amgen; LEO Pharma; MSD Oncology; MSD Oncology; MSD Oncology |
|
|
Honoraria - Sanofi; SERVIER |
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; SERVIER |
Research Funding - Bayer (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck |
|
|
Honoraria - Amgen; AstraZeneca; Merck Serono; Sanofi |
Consulting or Advisory Role - Amgen; Merck Serono; Pierre Fabre |
Travel, Accommodations, Expenses - Amgen; Roche; Servier/Pfizer |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bayer; Daiichi Sankyo; Epizyme; IPSEN; Lilly; Novartis; Roche |
Consulting or Advisory Role - Bayer; Daiichi Sankyo; Epizyme; Immune Design; Lilly; Roche |
Research Funding - AstraZeneca/MedImmune; Bayer; Merck Serono; Merck Serono; MSD Oncology; PharmaMar; Roche |
Patents, Royalties, Other Intellectual Property - Bristol-Myers Squibb |